BR9812138A - Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta - Google Patents

Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta

Info

Publication number
BR9812138A
BR9812138A BR9812138-3A BR9812138A BR9812138A BR 9812138 A BR9812138 A BR 9812138A BR 9812138 A BR9812138 A BR 9812138A BR 9812138 A BR9812138 A BR 9812138A
Authority
BR
Brazil
Prior art keywords
methods
compositions
interferon
beta
secreted proteins
Prior art date
Application number
BR9812138-3A
Other languages
English (en)
Portuguese (pt)
Inventor
James G Barsoum
Xiao-Qiang Qin
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of BR9812138A publication Critical patent/BR9812138A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9812138-3A 1997-08-29 1998-08-25 Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta BR9812138A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5725497P 1997-08-29 1997-08-29
PCT/US1998/017606 WO1999010516A2 (en) 1997-08-29 1998-08-25 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta

Publications (1)

Publication Number Publication Date
BR9812138A true BR9812138A (pt) 2000-07-18

Family

ID=22009467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812138-3A BR9812138A (pt) 1997-08-29 1998-08-25 Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta

Country Status (24)

Country Link
EP (1) EP1007717B8 (enExample)
JP (3) JP4124565B2 (enExample)
KR (1) KR100699285B1 (enExample)
CN (1) CN100342019C (enExample)
AT (1) ATE316145T1 (enExample)
AU (1) AU740428B2 (enExample)
BR (1) BR9812138A (enExample)
CA (1) CA2300480C (enExample)
CY (1) CY1105029T1 (enExample)
CZ (2) CZ297314B6 (enExample)
DE (1) DE69833264T2 (enExample)
DK (1) DK1007717T3 (enExample)
EA (1) EA003256B1 (enExample)
EE (1) EE04873B1 (enExample)
ES (1) ES2257817T3 (enExample)
HU (1) HU224422B1 (enExample)
IL (2) IL134593A0 (enExample)
IS (1) IS2318B (enExample)
NO (1) NO20000990L (enExample)
NZ (1) NZ503401A (enExample)
PT (1) PT1007717E (enExample)
SK (1) SK286821B6 (enExample)
TR (1) TR200000532T2 (enExample)
WO (1) WO1999010516A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1363676B1 (en) * 2001-01-22 2007-03-28 Biogen Idec MA Inc. Method of enhancing delivery of a therapeutic nucleic acid
US8058248B2 (en) * 2001-04-26 2011-11-15 The United States Of America As Represented By The Secretary Of Agriculture Foot and mouth disease virus vaccine comprising interferons
CN1388248A (zh) * 2001-05-25 2003-01-01 钱其军 高效表达干扰素的肿瘤细胞内特异性增殖的腺病毒及其构建方法
EP1835032A1 (en) * 2006-03-14 2007-09-19 Université de Liège A self-inactivating recombinant lentiviral vector for the inhibition of HIV replication
MD24Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului neinvaziv al glandei mamare
MD36Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului ductal in situ neinvaziv al glandei mamare
MD35Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de apreciere a riscului dezvoltării carcinomului neinvaziv in situ al glandei mamare
MD23Z (ro) * 2008-12-02 2010-01-31 Василе ЖОВМИР Metodă de tratament diferenţiat al carcinomului lobular in situ neinvaziv al glandei mamare
CN103505722B (zh) * 2012-06-19 2016-04-13 苏州丁孚靶点生物技术有限公司 干扰素在治疗/预防对常规抗肿瘤疗法有抗性的肿瘤中的用途及相关的产品和方法
WO2017214706A1 (en) * 2016-06-15 2017-12-21 Tissue Regeneration Therapeutics Inc. Anti-cancer use of genetically modified human umbilical cord perivascular cells (hucpvc)
CN114630670B (zh) * 2019-06-01 2025-03-11 西韦克生物技术有限责任公司 用于将基因编辑系统递送至真核细胞的细菌平台

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US6204052B1 (en) * 1994-08-16 2001-03-20 Introgene B.V. Adenoviral vectors with reduced TNF response and partial E3 region deletion
US5952221A (en) * 1996-03-06 1999-09-14 Avigen, Inc. Adeno-associated virus vectors comprising a first and second nucleic acid sequence

Also Published As

Publication number Publication date
TR200000532T2 (tr) 2000-11-21
AU740428B2 (en) 2001-11-01
HK1029599A1 (en) 2001-04-06
IS2318B (is) 2007-11-15
NZ503401A (en) 2003-01-31
HUP0002913A3 (en) 2003-08-28
CN100342019C (zh) 2007-10-10
EP1007717B1 (en) 2006-01-18
IL134593A0 (en) 2001-04-30
IL134593A (en) 2007-06-17
JP2005225888A (ja) 2005-08-25
NO20000990D0 (no) 2000-02-28
CA2300480C (en) 2010-01-05
CA2300480A1 (en) 1999-03-04
KR100699285B1 (ko) 2007-03-26
JP4219335B2 (ja) 2009-02-04
DE69833264D1 (de) 2006-04-06
WO1999010516A2 (en) 1999-03-04
EE04873B1 (et) 2007-08-15
DE69833264T2 (de) 2006-09-28
ATE316145T1 (de) 2006-02-15
PT1007717E (pt) 2006-06-30
IS5374A (is) 2000-02-11
CN1271391A (zh) 2000-10-25
EA003256B1 (ru) 2003-02-27
SK286821B6 (sk) 2009-06-05
KR20010023511A (ko) 2001-03-26
AU9205198A (en) 1999-03-16
HU224422B1 (hu) 2005-08-29
JP2004155786A (ja) 2004-06-03
CY1105029T1 (el) 2010-03-03
WO1999010516A3 (en) 1999-05-06
EE200000102A (et) 2000-12-15
CZ2000733A3 (cs) 2000-06-14
EP1007717A2 (en) 2000-06-14
JP4124565B2 (ja) 2008-07-23
HUP0002913A2 (hu) 2000-12-28
JP2001514010A (ja) 2001-09-11
JP3953458B2 (ja) 2007-08-08
EA200000270A1 (ru) 2000-10-30
ES2257817T3 (es) 2006-08-01
EP1007717B8 (en) 2006-05-03
CZ299095B6 (cs) 2008-04-23
NO20000990L (no) 2000-05-02
CZ297314B6 (cs) 2006-11-15
DK1007717T3 (da) 2006-05-29
SK2482000A3 (en) 2000-08-14

Similar Documents

Publication Publication Date Title
ES2147553T3 (es) Vectores virales recombinantes para la expresion en unas celulas musculares.
ATE169959T1 (de) Anthrax-toxin-fusionsproteine und deren verwendungen
ATE197719T1 (de) Verwendung von mesothelialen zellen in der gentherapie
DK0910647T3 (da) Human DNase i hyperaktive varianter
BR9812138A (pt) Métodos e composições para terapias empregando genes codificando proteìnas segregadas tal como interferon-beta
DE69830251D1 (de) Langes pentraxin ptx3 enthaltende pharmazeutische zusammensetzungen
BR9813753A (pt) "processo para complexo ifnar2/ifn"
DE60039677D1 (de) Akt-3 nukleinsäure, polypeptide und deren verwendung
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
WO2002050111A3 (en) Isolated laminin 10
DE69910809D1 (de) Verwendung von OmpA Enterobakterproteinen um zielgerichtet Antigen-Präsentierende Zellen anzusteuern
HUP0001057A2 (hu) A szarvasmarhafélék laktációjával összefüggő fehérje (CD14), az azt kódoló gén és a fehérje B-sejt-aktiválásban való alkalmazása
DK0676413T3 (da) Inteferon-alfa/beta-bindingsprotein, dets fremstilling og anvendelse
WO2000006735A8 (en) Interferon alpha hybrids
DK0811068T3 (da) Humane DNase I varianter
ATE342972T1 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
BR9810046A (pt) Sequência de nucleotìdeos, vetor de expressão, célula hospedeira, proteìna de esperma de mamìfero, proteìna de esperma recombinante, proteìna 4, 1 e/ou 6,7 de esperma, composição farmacêutica, e, vacina contraceptiva

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA, INC. (US)

Free format text: ALTERADO DE: BIOGEN, INC.

B25D Requested change of name of applicant approved

Owner name: BIOGEN IDEC MA INC. (US)

Free format text: ALTERADO DE: BIOGEN IDEC MA, INC.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: O DEPOSITANTE DEIXOU DE APRESENTAR MANIFESTACAO SOBRE O PARECER NEGATIVO DE FOLHAS 278 A 283 PUBLICADO NA RPI N.O 1972, DE 21/10/2008. ASSIM, DE ACORDO COM O ART. 36 DA LPI (LEI 9279/96) 2O, O PEDIDO VOLTA A EXAME SENDO CONSIDERADO NAO PATENTEAVEL PELAS RAZOES EXPOSTAS NO PARECER TECNICO ANTERIOR. PORTANTO, INDEFIRO O PRESENTE PEDIDO.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.